AI Model Predicts Pluvicto Response in Prostate Cancer
A multimodal AI model developed by nference combines PSMA-PET imaging and lab data to forecast treatment outcomes in advanced prostate cancer.
Updated on Nov. 18, 2026 in Cancer

Live Poll
Would you trust an AI tool to help your doctor choose your cancer treatment?
nference has developed a multimodal artificial intelligence model that predicts how metastatic castration-resistant prostate cancer patients will respond to Pluvicto. The findings were presented at a conference on Wednesday afternoon.
Why it matters
Pluvicto is a targeted radiotherapy for advanced prostate cancer, and identifying likely responders before treatment could help clinicians decide who is most likely to benefit. The approach combines imaging and routine laboratory data already present in electronic health records.
The model was developed and validated on 302 mCRPC patients who received at least three Pluvicto cycles, and it reached an AUC of 0.80 versus 0.73 for clinical features alone. Whether these results hold in prospective trials or broader populations has not been established.
The players
nference
nference is a health-focused artificial intelligence company headquartered in India that develops AI tools for analyzing clinical and medical data.
The details
The model pairs pretreatment PSMA-PET imaging features, including lesion shape, standardized uptake values and tumor uptake heterogeneity, with ten laboratory values from electronic health records. PSA value, lymphocyte count and SUV mean were among the most predictive features, and responders showed about 79% 30-month survival compared with about 34% for nonresponders.
Timeline
Findings were presented at a conference on Wednesday afternoon.
Treatment Landscape
Pluvicto, a PSMA-targeted radioligand therapy, has become an established option for metastatic castration-resistant prostate cancer, and tools that predict response could refine how it is allocated. This AI model extends that therapy's clinical use by estimating responder status before treatment begins.
For patients with advanced prostate cancer, a tool that estimates likely Pluvicto response before treatment could inform decisions about whether this therapy is worth pursuing. The model relies on imaging and laboratory tests that are already part of routine care.
The takeaway
Routine lab values and existing PSMA-PET scans may help clinicians anticipate which advanced prostate cancer patients will benefit from Pluvicto. Results still require prospective confirmation before they shape treatment decisions.
Further reading
Explore more on Cancer research and treatment advances.
Live Poll
Would you trust an AI tool to help your doctor choose your cancer treatment?



